USPTO trademark

MAZIE

Under examinationUSPTOWord markClass 1Class 5Class 42Class 44

"MAZIE" is a word mark owned by Seqirus Inc., filed at the USPTO on June 3, 2026. It is under examination and covers classes 1, 5, 42 and 44.

View Seqirus Inc. portfolioGet this data via the API
Official USPTO record
MAZIE trademark as filed
As filed with the USPTO
Status
Under examination
Since October 14, 2026
Filed
June 3, 2026
Registered
Not yet
Expires
Not recorded
Application no.
99862452
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
4 classes
Ownership

Who owns MAZIE

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Seqirus Inc.

Holly Springs, United States

231 trademarks in the portfolioView company

Representative

Nancy Sabarra

Fross Zelnick Lehrman & Zissu, P.C.

Goods and services

What the mark covers

The products and services MAZIE is filed for, grouped by Nice class.

  • Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders

  • Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells

  • Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines

  • Medical services; medical information; providing a website featuring medical information

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Notification of non-final action e-mailed
  2. Non-final action e-mailed
  3. Non-final action written
  4. Assigned to examiner
  5. New application office supplied data entered
  6. Application filing receipt mailed
  7. New application entered
FAQ

About MAZIE

Who owns the trademark "MAZIE"?

The USPTO trademark "MAZIE" (application 99862452) is owned by Seqirus Inc.

What is the status of "MAZIE"?

Its status at the USPTO is: under examination.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull MAZIE and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019e9633-6ec2-706b-9568-59798b14d569
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019e9633-6ec2-706b-9568-59798b14d569",
  "object": "trademark",
  "mark_text": "MAZIE",
  "status": {
    "primary": "pending",
    "stage": "examining"
  },
  "office_code": "US",
  "application_number": "99862452",
  "filing_date": "2026-06-03",
  "nice_classes": [
    1,
    5,
    42,
    44
  ],
  "owners": [
    {
      "name": "Seqirus Inc.",
      "entity_id": "ent_019eb7d7-073e-746b-967e-2a965cfa764c"
    }
  ]
}